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HYPITAT and the 
fallacy of pregnancy 
interruption
Hypertension in pregnancy is not 
a symptom but a sign elicited by 
screening asymptomatic women. 
Blood pressure rises physiologically 
towards term, and is a continuous 
variable. Hypertension can indicate pre-
eclampsia in a minority, but is imperfect 
in isolation, requiring conﬁ rmation by 
proteinuria. The (much more common) 
physiologies of well hypertensive 
pregnant women are fundamentally 
and radically diﬀ erent from those of 
women with pre-eclampsia, who have 
signiﬁ cant alterations in biochemistry 
and haemodynamics.
HYPITAT (Sept 19, p 979)1 is 
fatally ﬂ awed by the logical fallacy 
of using hypertension as both an 
entry and major endpoint criterion in 
determining whether interruption of 
pregnancy advantages the mother in 
ways that matter. Induction will lead to 
earlier resolution of most pregnancy-
associated signs (eg, varicose veins) 
without us knowing whether morbidity 
is lessened.
Donna Johnson’s associated 
Comment2 rightly reads as an apology 
for a small trial in which two-thirds did 
not have pre-eclampsia at entry and 
the composite measure of maternal 
morbidity was inadequate. Potential ill 
eﬀ ects on the baby were not powered 
for; the intervention led to signiﬁ cantly 
smaller babies (270 g lighter, equivalent 
to >8% of birthweight). We ignore at 
our peril the lesson of unexpected child 
harm, which is only demonstrable in 
large trials with long-term outcomes.3
In otherwise well women, producing 
less severe hypertension alone would 
not justify early delivery. HYPITAT has 
not determined optimum manage-
ment, yet the UK National Institute 
for Health and Clinical Excellence is 
using these data to determine clinical 
practice.4 We are seriously concerned 
about the heterogeneity of the 
population studied, and the potential 
to interfere with normal pregnancies.
AS is an external adviser to the NICE hypertensive 
disorders in pregnancy guideline development group.
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had an induction of labour; the other 
half awaited spontaneous delivery. 
Obviously, the attending obstetricians 
were either in doubt or had discordant 
views about this situation. In our 
opinion, this was not so much 
related to the fact that gestational 
hypertension is fundamentally 
diﬀ erent from pre-eclampsia. Like 
women with pre-eclampsia, those 
with gestational hypertension and 
their neonates are at increased risk 
of morbidity and mortality,1 and, 
moreover, daily practice is imperfect in 
distinguishing both disorders.2
As stated in our paper, there 
was little clinical evidence on how 
to handle this situation, which 
unfortunately is not uncommon in 
obstetrics. Even so, it is not unusual to 
power a trial on surrogate endpoints if 
the alternative options—ie, either not 
doing a trial or failing to complete a 
(non-feasible) mega-trial—do not help 
in solving the clinical problem.
The intervention used in our study 
reduces the chance of already hyper-
tensive women lingering in a potential 
hazardous situation, as deﬁ ned in our 
primary outcome. We found a tendency 
towards a lower caesarean section rate 
overall, and no evidence for higher 
caesarean section rates in the subgroup 
of women without proteinuria.
Finally, who would not agree with 
Bewley and Shennan on the need for 
long-term follow-up? This was until 
recently not feasible in our setting, 
as was the case for a large number of 
past obstetric intervention trials, also 
by our critics.
In view of our ﬁ ndings, we, as 
well as the UK National Institute for 
Health and Clinical Excellence,3 now 
recommend induction of labour in 
women with gestational hypertension 
or pre-eclampsia beyond an admit-
tedly somewhat arbitrary threshold of 
37 weeks’ gestation. However, the data 
are presented with transparency, thus 
allowing everybody to draw their own 
conclusions, and, awaiting new data, 
do better for mothers and children.
We declare that we have no conﬂ icts of interest.
Authors’ reply
We appreciate the comment by Susan 
Bewley and Andrew Shennan, since 
we share the same interest in not 
interfering with normal pregnancies. 
Not coincidentally, we positioned 
our trial in the context of strong 
practice variation for women with 
mild hypertensive disease at term in 
our country. Before our study, 50% of 
women in the Netherlands who were 
diagnosed with gestational hyper-
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Health research in 
Latin America
Anastasia Moloney (Sept 26, p 1053)1 
identiﬁ es gaps and weaknesses in 
Latin America’s health research, and 
indicates that integrated systems will 
help boost the amount and quality of 
health research produced in the region. 
We would like to highlight some recent 
developments, stimulated by the ﬁ rst 
Latin American Conference on Research 
and Innovation for Health2 in Rio de 
Janeiro, Brazil, in April, 2008.
Since Rio, regional agreements3 and 
policies have been developed, and 
several countries have advanced the 
development of their research agendas 
and strengthened their capacities. For 
example: Paraguay is working towards 
a formal health research system; 
El Salvador has included a section on 
health research in its national health 
policy; Guatemala has established a 
coordinating oﬃ  ce for health research 
within the Ministry of Health; and 
Uruguay has announced the launch of a 
sectoral fund for health research. Other 
countries are implementing strategies 
that strengthen coordin ation and 
communication, and are sharing and 
learning from each other’s experience.4 
These topics, and advances since the 
conference in Rio, were reviewed in 
a meeting on Nov 15–16, 2009, in 
Havana, Cuba.
The Council on Health Research 
for Develop ment (COHRED), and the 
Pan-American Health Organization 
(PAHO) are collaborating to support 
the strengthen ing of national health 
research systems in the region. The 49th 
Directing Council of PAHO approved 
on Sept 30, 2009, the PAHO Policy on 
Research for Health.5 The approval of 
this policy re-emphasises the need for 
a systems focus for research develop-
ment in the region, and shows commit-
ment by health authorities to providing 
adequate governance and stewardship. 
The political support provided by PAHO 
and its Directing Council (in which all 
Member States are represented) will 
further help advance research in the 
region. Furthermore, COHRED and 
PAHO are working with countries in the 
region to use management and bench-
marking tools such as Health Research 
Web to provide access to information 
and to facilitate exchange on national 
systems for health research.
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Anastasia Moloney1 reports on the 
overall diﬃ  culties faced by health 
research in Latin America.
During the late 1960s, the Chilean 
government acknowledged the 
national need for research and 
development and created CONICYT—a 
funding agency that has allocated 
substantial eﬀ orts and funds to 
support competitive science in our 
country. However, most of the funding 
provided by CONICYT for health 
research is currently directed towards 
basic mechanisms of disease and led 
by an increasing number of academics 
with no medical training.2 Furthermore, 
new science and technology centres of 
excellence are essentially dedicated 
to basic biomedical research. This 
situation has negatively aﬀ ected the 
relative contribution of physician 
scientists, particularly those focused on 
clinical and public health research, who 
are becoming an endangered species 
in our academic environment.
To amend these circumstances, 
the Ministry of Health and CONICYT 
launched in 2002 a new health 
research initiative: the National 
Fund for Health Research (FONIS), a 
programme with separate allocation 
of resources aimed at strengthening 
investigation in health knowledge and 
technology relevant for our country. 
This change in the research political 
agenda is deﬁ ning new scientiﬁ c 
priorities, supporting new training 
opportunities, and providing research 
funding focused on signiﬁ cant health 
problems that aﬄ  ict our population.
We praise the vision of key 
governmental and academic players 
that have redeﬁ ned the national 
health research map, which must 
increase the amount, quality, and local 
impact of health research in Chile and 
could be used as a model for other 
countries within our region.
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